News and Trends 22 Jun 2015
Kamada and Baxter extend their collaboration in Lung Transplant
The Israeli biotech Kamada and Baxalta, Baxter’ subsidiary will jointly co-fund a trial test to find out whether Kamada’s candidate is capable of preventing lung transplant rejection. Kamada, a plasma-derived protein therapeutics company focused on orphan indications, will carry out a Phase I/II clinical trial of its candidate alpha-1 antirypsin (AAT). The protein was already approved for […]